Dianthus Therapeutics (NASDAQ:DNTH) Earns Buy Rating from Guggenheim

Guggenheim reiterated their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research note published on Wednesday,Benzinga reports. They currently have a $84.00 price target on the stock.

Several other equities analysts have also recently commented on DNTH. TD Cowen assumed coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating for the company. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Dianthus Therapeutics has an average rating of “Buy” and an average target price of $52.14.

Dianthus Therapeutics Stock Performance

NASDAQ:DNTH opened at $21.90 on Wednesday. Dianthus Therapeutics has a 52-week low of $18.13 and a 52-week high of $33.77. The firm has a market cap of $648.17 million, a price-to-earnings ratio of -8.76 and a beta of 1.82. The business’s fifty day moving average is $22.65 and its 200 day moving average is $24.94.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. Equities analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in shares of Dianthus Therapeutics in the 3rd quarter worth approximately $556,000. Barclays PLC boosted its stake in Dianthus Therapeutics by 390.5% during the 3rd quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after purchasing an additional 33,185 shares during the last quarter. HighVista Strategies LLC purchased a new stake in Dianthus Therapeutics during the 3rd quarter valued at $542,000. State Street Corp boosted its stake in Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after purchasing an additional 413,425 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after acquiring an additional 97,362 shares during the period. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.